Effects of long-term hormone replacement therapy: Results from a cohort study

被引:0
作者
Signorelli, S. S. [1 ]
Sciacchitano, S. [2 ]
Anzaldi, M. [1 ]
Fiore, V. [1 ]
Catanzaro, S. [1 ]
Simili, M. [1 ]
Neri, S. [3 ]
机构
[1] Univ Catania, Fac Med, Dept Internal Med & Syst Dis, Sect Internal & Vasc Med, Catania, Italy
[2] Univ Catania, Fac Med, Dept Obstet & Gynecol & Radiol Sci, Catania, Italy
[3] Univ Catania, Fac Med, Dept Internal Med & Syst Dis, Sect Internal Med, Catania, Italy
关键词
Post-menopause; HRT; cardiovascular events; risk factors; intima media thickness; ENDOTHELIUM-DEPENDENT VASODILATION; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; NORETHISTERONE ACETATE; CARDIOVASCULAR-DISEASE; ESTROGEN REPLACEMENT; NITRIC-OXIDE; DOUBLE-BLIND; RISK; PREVENTION;
D O I
10.1007/BF03347063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The positive effects of hormonal replacement therapy (HRT) in protecting the cardiovascular system in women have been supported by several observational studies, while also being questioned by other randomized controled trials. Today, it is unclear whether HRT plays a crucial role, or even whether there is any role at all, for this therapy in preventing or in lowering cardiovascular disease (CVD). In the present study, we have evaluated the effectiveness of long-term HRT in post-menopausal women on the incidence of cardiovascular events and arterial remodeling, as well as on some metabolic factors. Eighty-four post-menopausal women (mean age: 46.3 +/- 5.2; age range: 42-66 yr) underwent HRT for 10.9 +/- 1.2 yr (range: 8-12 yr). None of these subjects showed new cardiovascular events, and we found a reduction of the intima-media thickness (baseline: 1.39 +/- 0.2, 1.35 +/- 0.2, 1.31 +/- 0.2 mm) and total cholesterol, LDL and antithrombin III levels were lower, while HDL and fibrinogen levels increased. The study highlights a number of positive effects both on vascular conditions and metabolic and coagulative markers that are usually considered as generic and crucial risk factors for CVD. The relatively low number of patients is perhaps a limitation of this study, however, the long-term period of follow-up should be considered an interesting and important factor. Furthermore, this study underlines the real-life clinical experience of a Menopause Center. (J. Endocrinol. Invest. 34: 180-184, 2011) (C) 2011, Editrice Kurtis
引用
收藏
页码:180 / 184
页数:5
相关论文
共 50 条
  • [31] Morbidity in patients on long-term steroid replacement therapy
    Druce, M. R.
    Akker, S. A.
    Chew, S. L.
    Drake, W. M.
    Grossman, A. B.
    CLINICAL ENDOCRINOLOGY, 2010, 72 (04) : 564 - 566
  • [32] COMPLIANCE WITH LONG-TERM ORAL HORMONAL REPLACEMENT THERAPY
    EIKEN, P
    KOLTHOFF, N
    MATURITAS, 1995, 22 (02) : 97 - 103
  • [33] Hormone replacement therapy and cancer survival: a longitudinal cohort study: protocol paper
    Ranger, Tom Alan
    Burchardt, Judith
    Clift, Ashley Kieran
    Mei, Winnie Xue
    Coupland, Carol
    Tan, Pui San
    Dixon, Sharon
    Cardwell, Christopher Robert
    Hippisley-Cox, Julia
    BMJ OPEN, 2021, 11 (08):
  • [34] Effects of long-term oral hormone replacement therapy on plasma nitric oxide and beta-endorphin levels in postmenopausal women
    Akhan, SE
    Gürel, T
    Has, R
    Iyibozkurt, AC
    Turfanda, A
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2002, 54 (04) : 196 - 200
  • [35] Risk of stroke and hormone replacement therapy -: A prospective cohort study
    Li, C
    Engström, G
    Hedblad, B
    Berglund, G
    Janzon, L
    MATURITAS, 2006, 54 (01) : 11 - 18
  • [36] Hormone replacement therapy and coronary heart disease: Results of randomized trials
    Petitti, D
    PROGRESS IN CARDIOVASCULAR DISEASES, 2003, 46 (03) : 231 - 238
  • [37] Long-term Postmenopausal Hormone Therapy and Endometrial Cancer
    Razavi, Pedram
    Pike, Malcolm C.
    Horn-Ross, Pamela L.
    Templeman, Claire
    Bernstein, Leslie
    Ursin, Giske
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (02) : 475 - 483
  • [38] Intensity of statin therapy after ischaemic stroke and long-term outcomes: a nationwide cohort study
    Kyto, Ville
    Aivo, Julia
    Ruuskanen, Jori O.
    STROKE AND VASCULAR NEUROLOGY, 2024, : 142 - 145
  • [39] Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study
    Brett, KM
    Madans, JH
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1997, 145 (06) : 536 - 545
  • [40] Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study
    Savendahl, Lars
    Cooke, Rosie
    Tidblad, Anders
    Beckers, Dominique
    Butler, Gary
    Cianfarani, Stefano
    Clayton, Peter
    Coste, Joel
    Hokken-Koelega, Anita C. S.
    Kiess, Wieland
    Kuehni, Claudia E.
    Albertsson-Wikland, Kerstin
    Deodati, Annalisa
    Ecosse, Emmanuel
    Gausche, Ruth
    Giacomozzi, Claudio
    Konrad, Daniel
    Landier, Fabienne
    Pfaeffle, Roland
    Sommer, Grit
    Thomas, Muriel
    Tollerfield, Sally
    Zandwijken, Gladys R. J.
    Carel, Jean-Claude
    Swerdlow, Anthony J.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (08) : 683 - 692